FDA lets device makers go digital-only on safety labels—with a paper-request escape hatch

What it does

This bill allows manufacturers of medical devices to provide required labeling (instructions, warnings, dosage information) electronically instead of on paper, provided users can easily access it online and request paper copies at no cost. The FDA retains authority to require paper labels or additional safeguards for high-risk devices used without professional supervision. The bill does not change what information must be disclosed—only the medium through which it is delivered.

Why we flagged it

The bill modernizes FDA labeling rules by permitting electronic delivery of required device information, reducing paper-printing costs for manufacturers while preserving FDA safety authority and patient access rights. It is a straightforward regulatory update, not a deregulation or carve-out.

What the text implies

• Digital-only labeling may disadvantage patients without reliable internet access, older adults unfamiliar with digital interfaces, and those in rural areas with poor connectivity—the bill does not mandate plain-language or accessibility testing.
• The term 'user-friendly access' is undefined in the bill; FDA must define it by regulation, creating a post-enactment rulemaking burden and potential for weak standards if industry lobbies for minimal compliance.
• Manufacturers may use digital labeling to bury warnings in hyperlinks or nested menus, reducing visibility compared to paper labels where warnings are prominent—the bill requires 'easy access' but not prominent display.
• The 2-year public comment period (Section 3) suggests the FDA has not yet determined best practices for digital device labeling, meaning the bill may be premature and implementation could be chaotic.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Citizens retain access to all required safety information and can request paper copies free of charge, which is a modest convenience gain for digitally literate users and a cost savings for manufacturers that may lower device prices. However, digital-only defaults create barriers for elderly, low-literacy, uninsured, or rural populations with poor internet access, and the bill does not mandate plain-language digital labeling or test usability with actual patients—only that access be 'user-friend

Who stands to gain

• medical device manufacturers (reduced printing and distribution costs)
• digital health platforms and software vendors (potential contracts to host labeling)

Named in the bill

FDA (Food and Drug Administration), HHS (Department of Health and Human Services), medical device manufacturers, in vitro diagnostic device manufacturers, Federal Food, Drug, and Cosmetic Act Section 502(f)

Where it stands

1 cosponsor: 1 Democrats.

• May 13, 2026 — Introduced · Congress.gov: “Introduced in Senate”
• May 13, 2026 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

2 lobbying clients named this bill on 2 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $1,820,000 in lobbying spend. A filing names 12 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 41% of bills with at least one filing.

Jim Banks, the sponsor, reported $559,626 in PAC receipts in the 2026 cycle.

• Medtronic Inc — $1,180,000 on 1 filing
• Philips Holding USA Inc. — $640,000 on 1 filing

Lobbying Disclosure Act filings through Jul 21, 2026. A filing shows who paid to lobby on a bill it names, not what changed.